Top

Open Access 04-02-2025 | Maturity-Onset Diabetes of the Young | Rapid Communication

Efficacy and safety of SGLT2 inhibitors in the treatment of maturity-onset diabetes of the young (MODY): a case report and literature review

Authors: Michelle Bombonato, Guglielmo Beccuti, Andrea Benso, Beatrice Giannone, Silvana Bertaina, Fabio Broglio, Fabio Bioletto

Published in: Hormones

Abstract

Background

Sulfonylureas constitute the standard therapy for patients with HNF1A-MODY (maturity-onset diabetes of the young) but are characterized by an increased risk of hypoglycemia. While SGLT2 inhibitors (SGLT2i) may potentially represent a useful therapeutic option, data from the literature are scant.

Case presentation

We report the case of a young woman affected by HNF1A-MODY who was successfully and safely treated with an SGLT2i in addition to sulfonylurea. After SGLT2i initiation, an improvement in the patient’s glycemic control was observed and was maintained over time. No adverse effects were noted and, in particular, no increase in ketonemia or ketonuria occurred.

Conclusions

The use of SGLT2i under controlled circumstances may represent a useful therapeutic option in patients with HNF1A-MODY.

Available only for authorised users

Colclough K, Van Heugten R, Patel K (2022) An update on the diagnosis and management of monogenic diabetes. Pract Diabetes 39:42–48. https://doi.org/10.1002/pdi.2410CrossRef

Riddle MC, Philipson LH, Rich SS et al (2020) Monogenic diabetes: from genetic insights to Population-Based Precision in Care. Reflections from a diabetes care editors’ Expert Forum. Diabetes Care 43:3117–3128. https://doi.org/10.2337/dci20-0065CrossRefPubMedPubMedCentral

Zelniker TA, Wiviott SD, Raz I et al (2019) SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet Lond Engl 393:31–39. https://doi.org/10.1016/S0140-6736(18)32590-XCrossRef

Valkovicova T, Skopkova M, Stanik J, Gasperikova D (2019) Novel insights into genetics and clinics of the HNF1A-MODY. Endocr Regul 53:110–134. https://doi.org/10.2478/enr-2019-0013CrossRefPubMed

Sriravindrarajah A, Fernandes A, Wu T, Hocking S (2021) The use of SGLT2 inhibitors in achieving glycaemic control in maturity-onset diabetes of the young type 3. Endocrinol Diabetes Metab Case Rep 2021:21–0102 EDM-21–0102. https://doi.org/10.1530/EDM-21-0102CrossRefPubMedPubMedCentral

Hohendorff J (2017) A single dose of dapagliflozin, an SGLT-2 inhibitor, induces higher glycosuria in GCK- and HNF1A-MODY than in type 2 diabetes mellitus

Broome DT, Pantalone KM, Kashyap SR, Philipson LH (2021) Approach to the patient with MODY-Monogenic diabetes. J Clin Endocrinol 106

Phan F, Bourron O, Laroche S et al (2021) Euglycaemic diabetic ketosis decompensation under dapagliflozin in a patient with MODY3. Diabetes Metab 47:101248. https://doi.org/10.1016/j.diabet.2021.101248CrossRefPubMed

Nakamura A (2022) Effects of Sodium-glucose co-transporter-2 inhibitors on pancreatic β-Cell Mass and function. Int J Mol Sci 23:5104. https://doi.org/10.3390/ijms23095104CrossRefPubMedPubMedCentral

10.

American Diabetes Association Professional Practice Committee (2024) 2. Diagnosis and classification of diabetes: standards of Care in Diabetes-2024. Diabetes Care 47:S20–S42. https://doi.org/10.2337/dc24-S002CrossRef

11.

Zelniker TA, Wiviott SD, Raz I et al (2019) Comparison of the effects of Glucagon-Like peptide receptor agonists and sodium-glucose cotransporter 2 inhibitors for Prevention of Major adverse Cardiovascular and renal outcomes in type 2 diabetes Mellitus. Circulation 139:2022–2031. https://doi.org/10.1161/CIRCULATIONAHA.118.038868CrossRefPubMed

12.

Younes AM, Salem M, Maraey A et al (2022) Safety outcomes of SGLT2i in the heart failure trials: a systematic review and Meta-analysis. Int J Cardiol 366:51–56. https://doi.org/10.1016/j.ijcard.2022.06.059CrossRefPubMed

13.

Di Costanzo A, Esposito G, Indolfi C, Spaccarotella CAM (2023) SGLT2 inhibitors: a New Therapeutical Strategy to improve clinical outcomes in patients with chronic kidney diseases. Int J Mol Sci 24:8732. https://doi.org/10.3390/ijms24108732CrossRefPubMedPubMedCentral

14.

Lincoff AM, Brown-Frandsen K, Colhoun HM et al (2023) Semaglutide and Cardiovascular outcomes in obesity without diabetes. N Engl J Med 389:2221–2232. https://doi.org/10.1056/NEJMoa2307563CrossRefPubMed

15.

Irfan H (2024) Obesity, Cardiovascular Disease, and the Promising Role of Semaglutide: insights from the SELECT Trial. Curr Probl Cardiol 49:102060. https://doi.org/10.1016/j.cpcardiol.2023.102060CrossRefPubMed

Title: Efficacy and safety of SGLT2 inhibitors in the treatment of maturity-onset diabetes of the young (MODY): a case report and literature review
Authors: Michelle Bombonato
Guglielmo Beccuti
Andrea Benso
Beatrice Giannone
Silvana Bertaina
Fabio Broglio
Fabio Bioletto
Publication date: 04-02-2025
Publisher: Springer International Publishing
Keywords: Maturity-Onset Diabetes of the Young
Diabetes Therapy
Empagliflozin
Sulfonylurea
Diabetes
Endocrinology
Published in: Hormones
Print ISSN: 1109-3099
Electronic ISSN: 2520-8721
DOI: https://doi.org/10.1007/s42000-025-00632-8

At a glance: The STEP trials

Obesity
Clinical Trial Summary

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Podcast | Sexual health in older age

Springer Medicine

Abstract

Background

Case presentation

Conclusions

Please log in to get access to this content

At a glance: The STEP trials